Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04084080 · ClinicalTrials.gov registry record · Phase 3

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

A Phase 3 study of Sickle Cell Disease, sponsored by University of Pittsburgh.

Active
Registry status
Phase 3
Development phase
173
Enrollment target
20
Study locations

NCT04084080 is a Phase 3 study of Sickle Cell Disease that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 173 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04084080, a Phase 3 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by University of Pittsburgh.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
173 participants
Enrollment target
20
Study locations

Study Summary

The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.

Conditions Studied

Sickle Cell Disease

Interventions

  • OTHER Standard of care
  • BIOLOGICAL Red Blood Cell

Study Locations (20)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill
  • Atrium Health - Charlotte
  • Duke University - Durham
  • East Carolina University - Greenville

Maryland

  • University of Maryland - Baltimore
  • Johns Hopkins University - Baltimore

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Montefiore Medical Center - New York

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland
  • Ohio State University - Columbus

Alabama

  • University of Alabama - Tuscaloosa

California

  • UCSF Benioff Children's Hospital Oakland - Oakland

District of Columbia

  • Howard University Center for Sickle Cell Disease - Washington D.C.

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2020-02-26
Est. Completion 2026-05-31
Phase Phase 3

Sponsor

University of Pittsburgh

1,238 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04084080

The ClinicalTrials.gov registry entry for NCT04084080 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (41% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.

NCT04084080 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT04084080 about?

NCT04084080 is a clinical study titled "Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)". The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening...

What is the current status of trial NCT04084080?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2020-02-26. Estimated completion is 2026-05-31.

What conditions does trial NCT04084080 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT04084080?

The interventions under investigation include: Standard of care (OTHER), Red Blood Cell (BIOLOGICAL).

Who is sponsoring clinical trial NCT04084080?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04084080 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.